anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Thigh lift, first described by Lewis in 1957, consists of thigh recontouring by various strategies. In post-bariatric thigh lift (PBTL), the technical details become fundamental due to both patient comorbidities and increased risk of complications. Moreover, post-bariatric weight loss affects the thighs, resulting in significant tissue redundancy, inner excess, lower thigh deformity, later excess, and buttocks ptosis. With the present paper, a systematic review of PBTL procedures is reported and a comprehensive classification system is proposed, aiming to improve their medical and surgical management.
METHODS: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) systematic review was carried out by searching the PubMed (MEDLINE) database from May 2004 to May 2024 using the search string "thighplasty OR thigh lift OR post-bariatric thighplasty OR (thigh lift AND weight loss) OR (thigh lift AND liposuction)". Original studies discussing PBTL with a minimum of three clinical cases were eligible for inclusion.
RESULTS: The final synthesis included 17 articles and 496 patients. The articles were published in the last 20 years. Several papers discussed significant PBTL surgical strategies and technical measures.
CONCLUSIONS: PBTL is challenging because of both technical factors and complex comorbidities of post-bariatric patients. This comprehensive assessment of PBTL may help in choosing the appropriate treatment based on a patient's individual needs. Liposuction-assisted inner thigh lift with combined horizontal-vertical scars and skin-only excision is effective and versatile for most patients. However, select cases may benefit from alternative and more invasive strategies. Artificial intelligence is a topic of growing interest, and it will probably become increasingly relevant in PBTL.
Method and composition for treating painful conditions of the body and of the anorectal region. The compositions include a combination of nitroglycerin and sucralfate or a combination of nitroglycerin, lidocaine and sucralfate. The compositions also include a combination of an .alpha.-adrenergic blocker and sucralfate, a combination of a-adrenergic blocker and lidocaine, and a combination of an .alpha.-adrenergic blocker, lidocaine, and sucralfate. Alternatively, the composition may contain only an .alpha.-adrenergic blocker. Additional active ingredients for reduction of anal pain may be added to the composition, particularly capsaicin. The compositions may be included in a petrolatum base along with a water soluble lubricant. These compositions have been found effective in treating painful conditions in the anal region such as anal fissures, inflamed or recently thrombosed hemorrhoids, and chronic anal pain.
Patients must have newly diagnosed DIPG (a typical DIPG on MR imaging, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, without histologic confirmation; atypical DIPG undergoing a biopsy and the tumor is a diffuse glioma WHO Grade II-IV with OR without H3 K27M mutation; or pontine lesions that do not meet these MR imaging criteria with histologically confirmed diffuse glioma WHO Grade II-IV with H3 K27M- mutation). This arm will consist of two parts: a phase I component to evaluate the safety and tolerability of concurrent Optune and RT, and a phase II component to evaluate the feasibility of concurrent Optune and RT and the efficacy associated with this approach compared to historical controls.
Group 3 (absence of rehabilitation) will be made up of those patients who for any reason do not agree to participate in the rehabilitation program, such as those who do not live in the city, and will remain without intervention. All participants in this group will perform all the evaluations procedures, comprised of: heart rate variability, hematological and biochemical profile, erythrocytes membrane deformability and stability, inflammatory markers, respiratory pressures, plethysmography, spirometry, carbon monoxide diffusion capacity, ankle brachial index, electrical bioimpedance, echocardiogram, quality of life questionnaires (SF-36 and MacNew QLMI), cardiopulmonary exercise testing and constant load tests.
PURPOSE:To provide the titled mutant cell strain obtained by culturing a cell separated from a human hepatocarcinoma cell strain, capable of producing considerable amount of surface antigen against hepatitis virus B, culturable in a serum-free medium, and giving an antigen effective as a preventive vaccine to hepatitis B at a low cost. CONSTITUTION:A mutant cell strain huGK-14 capable of producing considerable amount of surface antigen against hepatitis virus B is separated from a human hepatocarcinoma cell strain, and the mutant strain is cultured. The mutant cell strain has a chromosome mode number of 51 and integrated with about 8 DNA fragment containing a gene coding an abr-type hepatitis virus B surface antigen based on one chromosome haploid. The cell is epithelial adhesive cell having irregular circular form and has optimum proliferation temperature of 36.5+ or -1 deg.C. The productivity of antigen increases rapidly after the cell density reaches saturated state. The proliferation of the cell is carried out preferably in a medium obtained by adding 10% serum to a DM-160 base medium, however, excellent proliferation can be attained even in a serum-free Williams E base medium.
The treatment schedule includes: (1) the priming step with two ID AlloStim® injections (Days 0 and 3), an additional two ID injections followed by IV infusion of AlloStim® (Days 7 and 10); (2) the vaccination step with cryoablation of a single metastatic lesion followed by injection of AlloStim® into the ablated tumor and IV infusion of AlloStim® on protocol day 14, followed by IV infusion of AlloStim® on Day 17 (3) the activation step with an IV study drug infusion on Day 21 and (4) the booster step with IV booster infusions of AlloStim® on days 49 and 77. Additional booster infusions can be administered monthly at the discretion of the Investigator.
FIELD: medicine, medicinal industry. SUBSTANCE: invention relates to production of preparations used for immunotherapy and immunoprophylaxis of bacterial and viral diseases. Blood plasma is fractionated with ethyl alcohol at low temperature, immunoglobulin- -containing precipitate is isolated and dissolved its in sodium chloride solution. Prothrombin precipitate is isolated by centrifugation, pH value of obtained supernatant is brought about to 5.3 ± 0.05 and ethyl alcohol is added to concentration 16-18% at simultaneous decrease of temperature to minus 5-6 C. Inert precipitate is removed by centrifugation, pH value of obtained supernatant is brought about to 5.9-6.0 and DEAE-Sephadex is added as measured for 6-10 ml/l of solution. Solution is incubated for 1-5 h, DEAE-Sephadex is removed by filtration and precipitate of the end product is obtained by alcohol precipitation. Precipitate is dissolved in physiological solution, then glycocol is added and sterilizing filtration is carried out. The final preparation of immunoglobulin G shows high degree of purity that decreases adverse response reactions in patients in its using. EFFECT: improved method of preparing, enhanced purity. 2 ex
Laser Ablation therapy (LA) using 810nm diode laser and Indocyanine Green (ICG) solution which efficiently absorbs laser energy and the increased temperature results in an instantaneous flame that chars tissue and microbes. Intracanal heating can potentially cause damage to cementum structure and periodontal tissues. The objective of this study is to observe possible changes in the periodontal ligament and cementum resulting from the use of LA with ICG as an adjuvant therapy to endodontic treatment. Ten patients with lower incisors requiring extraction will be selected. Before extraction, chemical-mechanical root canal preparation will be carried out with a single file reciprocating system (35/04) and 2.5% sodium hypochlorite solution. Then, the canals will be dried and filled with 0.05% ICG, which will remain in place for 1 minute (pre-irradiation time). For the test group, a #20 laser fiber will be inserted into the root canal to the working length. The 810 nm wavelength infrared diode laser is activated with a power of 2.5W, an interval of 300 ms, and a duration of 100 ms. After activation commences, circular movements are made for a period of 30 seconds together with the fiber removal movement. After the first activation, there is a 30-second pause and a new 30-second activation cycle will then be performed in the same way as the previous one. After treatment, the tooth element will be extracted and the apical third of the root with the periodontal ligament is processed for histological analysis using hematoxylin-eosin and picrosirius red staining to evaluate the morphological structures. Two teeth extracted without treatment will be used as controls.
Veterans receiving SUPPORT will be offered all modules of the intervention via weekly, 50-minute sessions with a Peer Specialist. Following the completion of a mental health evaluation by a licensed professional, the Peer Specialist leads the Veteran who is at risk for suicide through recovery planning that is tailored to the Veteran's suicidal experiences with cognitive learning strategies to enhance recall of the Veteran's safety plan and improve recovery.
BACKGROUND: Candidaemia is an invasive infection with high morbidity and mortality. All urology procedures carry risk of post-operative infection. Risk mitigation strategies include preoperative urine culture and treatment of cultured organism(s) regardless of symptoms. After zero cases of candidaemia for two years, there were five cases in elective urology patients within 15 weeks between June - September 2021. This increased incidence of candidaemia amongst these patients prompted multidisciplinary investigation.
METHODS: Single centre case series, in a 250-bed hospital which annually performs 2000-2500 elective urology surgeries. Affected patients were elderly with multiple comorbidities. Notably, four of five patients had prior indwelling ureteral stents. All five patients had preoperative bacteriuria requiring antibiotics and one patient had pre-operative candiduria.
RESULTS: Hypotheses including sterilisation failure, surgical instrument contamination, or surgical technique issues were unfounded. We propose that pre-operative duration of antibacterial therapy, particularly in the setting of ureteral stent biofilm, is a significant factor for candiduria. A new prescribing algorithm for urology patients was devised. Antibiotic treatment duration in asymptomatic patients with indwelling urinary tract foreign material was reduced from 14 to 3 days, and from 14 to 7 days in symptomatic patients. Dedicated pharmacist resources were allocated to support this change and pre-operatively manage these patients. These interventions led to zero candidaemia cases over the subsequent 21 months, along with zero post-operative bacterial bloodstream infections.
CONCLUSIONS: Prolonged pre-operative antibacterial therapy poses a risk for post-operative candidaemia, especially in patients with ureteral stents. Shortening pre-operative antibiotic courses, coupled with increased pharmacist involvement, effectively reduced candidaemia incidence.
A method for producing particles, from a substance, having predetermined size and/or morphology characteristics. The method consists of mixing within a spray nozzle a solution stream containing the substance in dissolved or dispersed form with a supercritical fluid stream. Spraying the mixture through a nozzle into a particle collecting chamber and there separating the particles. The characteristic feature is an additional step, providing a make-up agent (modifier) to the fluid stream, possibly combined with recycling of the fluid and/or performing the method essentially simultaneously in several spray nozzles. Additional features are also a production system comprising functions for performing the method above and the introduction of the make-up agent, recycling of the fluid and performing several runs essentially simultaneously in the same production system. Also a pharmaceutical formulation in which particles produced according to the method has been used for its manufacture.
OBJECTIVES: Microvascular invasion (MVI) is a recognized biomarker associated with poorer prognosis in patients with hepatocellular carcinoma. Dual-energy computed tomography (DECT) is a highly sensitive technique that can determine the iodine concentration (IC) in tumour and provide an indirect evaluation of internal microcirculatory perfusion. This study aimed to assess whether the combination of DECT with laboratory data can improve preoperative MVI prediction.
METHODS: This retrospective study enrolled 119 patients who underwent DECT liver angiography at 2 medical centres preoperatively. To compare DECT parameters and laboratory findings between MVI-negative and MVI-positive groups, Mann-Whitney U test was used. Additionally, principal component analysis (PCA) was conducted to determine fundamental components. Mann-Whitney U test was applied to determine whether the principal component (PC) scores varied across MVI groups. Finally, a general linear classifier was used to assess the classification ability of each PC score.
RESULTS: Significant differences were noted (P < .05) in alpha-fetoprotein (AFP) level, normalized arterial phase IC, and normalized portal phase IC between the MVI groups in the primary and validation datasets. The PC1-PC4 accounted for 67.9% of the variance in the primary dataset, with loadings of 24.1%, 16%, 15.4%, and 12.4%, respectively. In both primary and validation datasets, PC3 and PC4 were significantly different across MVI groups, with area under the curve values of 0.8410 and 0.8373, respectively.
CONCLUSIONS: The recombination of DECT IC and laboratory features based on varying factor loadings can well predict MVI preoperatively.
ADVANCES IN KNOWLEDGE: Utilizing PCA, the amalgamation of DECT IC and laboratory features, considering diverse factor loadings, showed substantial promise in accurately classifying MVI. There have been limited endeavours to establish such a combination, offering a novel paradigm for comprehending data in related research endeavours.
Parent patent described the use of pads of polyether foam of density 20 kg/cm3 and 23-27 pores/cm for dissipating alkyl halide refrigerants to chill teeth for dental treatment. Addition extends pad descriptions to flexible open celled foams of density 25-40, pref. 33 kg/cm3 and 10-20, pref. 15-19 pores/cm, specifically of polyester based polyurethane foam. The denser, less porous foam approx. doubles the period or the number of teeth effectively chilled for a pad of given volume drenched with a particular refrigerant.
The development of adequate sleep patterns is paramount to the optimal neurodevelopment, as well as to promote proper learning, develop memory and preserve cerebral plasticity. Factors that hinder sleep patterns can negatively influence the child's growth, neurological and motor development.

The investigators will conduct a randomized controlled trial within the 2015 Pelotas Birth Cohort. At the 3-month follow-up, children who sleep less than 13 hours per 24 hours (nighttime sleep and daytime naps) will be eligible for the study. The sample size was estimated at 276 children per arm. Nighttime self-regulated sleep duration will be evaluated at baseline (age 3 months) and at 6, 12 and 24 months using actigraphy and via a sleep diary completed by the mother. Following block randomization, mothers from the intervention group will be visited by a trained fieldworker who will deliver counseling on age-appropriate normal sleep behaviors, how to facilitate sleep onset and how to manage night awakenings.
In embryofetal development studies in rats and rabbits, oral administration of up to 100 mg/kg/day and 50 mg/kg/day, respectively, to pregnant animals throughout organogenesis produced no evidence of teratogenicity. These doses are equivalent to 49 (rat) and 48 (rabbit) times the maximum recommended human dose (MRHD) of 20 mg on a mg/m2 basis. In rats, pre-and postnatal growth was reduced in the offspring of dams receiving 100 mg/kg/day. This dose was also maternally toxic, as evidenced by clinical signs and decreased maternal body weight gain during gestation. The no-effect dose for rat offspring growth reduction was 10 mg/kg (a dose equivalent to 5 times the MRHD of 20 mg on a mg/m2 basis). No adverse effects on embryofetal development were observed in rabbits at the doses examined.

In a pre- and postnatal development study in rats, increased stillbirth and postnatal mortality, and decreased growth and physical development, were observed in the offspring of females treated with doses of 7 mg/kg/day or greater during the latter part of gestation and throughout lactation. There was no evidence of maternal toxicity at this dose. The no-effect dose for offspring development was 1 mg/kg/day (a dose equivalent to 0.5 times the MRHD of 20 mg on a mg/m2 basis). When the adverse effects on offspring viability and growth were examined in a cross-fostering study, they appeared to result from both in utero and lactational exposure to the drug.

There are no studies of zaleplon in pregnant women; therefore, Zaleplon is not recommended for use in women during pregnancy.
DFNA9 is a dominantly inherited form of adult-onset progressive hearing impairment caused by mutations in the COCH gene. COCH encodes cochlin, a crucial extracellular matrix protein. We established a genomically humanized mouse model for the Dutch/Belgian c.151C>T founder mutation in COCH. Considering upcoming sequence-specific genetic therapies, we exchanged the genomic murine Coch exons 3-6 for the corresponding human sequence. Introducing human-specific genetic information into mouse exons can be risky. To mitigate unforeseen consequences on cochlin function resulting from the introduction of the human COCH protein-coding sequence, we converted all human-specific amino acids to mouse equivalents. We furthermore optimized the recognition of the human COCH exons by the murine splicing machinery during pre-mRNA splicing. Subsequent observations in mouse embryonic stem cells revealed correct splicing of the hybrid Coch transcript. The inner ear of the established humanized Coch mice displays correctly-spliced wild-type and mutant humanized Coch alleles. For a comprehensive study of auditory function, mice were crossbred with C57BL/6 Cdh23753A>G mice to remove the Cdh23ahl allele from the genetic background of the mice. At 9 months, all humanized Coch genotypes showed hearing thresholds comparable to wild-type C57BL/6 Cdh23753A>G mice. This indicates that both the introduction of human wildtype COCH, and correction of Cdh23ahl in the humanized Coch lines was successful. Overall, our approach proved beneficial in eliminating potential adverse events of genomic humanization of mouse genes, and provides us with a model in which sequence-specific therapies directed against the human mutant COCH alle can be investigated. With the hearing and balance defects anticipated to occur late in the second year of life, a long-term follow-up study is ongoing to fully characterize the humanized Coch mouse model.
It is intended to provide a peroxisome proliferator-activated receptor (PPAR) activator, which is free from the problem of side effects, can be taken over a long term and has no characteristics taste. β-cryptoxantine is employed as a PPAR activator. β-cryptoxantine, which is contained in a large amount in the pulp of citrus fruits (in particular, mandarin-type citrus fruits) such as satsuma oranges, for example, has been consumed for many years. Thus, it is free from any problem in safety and has a low calorie content. Therefore, it can be taken over a long term. Because of being tasteless and odorless, moreover, β-cryptoxantine would not damage the unique taste when added to a food. Therefore, it can be added to foods and taken.
The invention provides a novel polypeptide for preparing hydrogel, the amino acid sequence of which is SEQ ID NO. 1. One specific nucleotide sequence of the gene for coding the polypeptide is SEQ ID NO. 2. The polypeptide provided by the invention is used for preparing hydrogel. The polypeptide provided by the invention is used for preparing hydrogel. The polypeptide is self-polymerized into gel in a short time, and the proper pore size and mechanical property of the polypeptide have great application potential in the aspects of soft tissue repair, drug sustained release, 3D cell scaffolds and the like.
The invention provides establishment, suspension domestication and application of a cat kidney CRFK adherent cell line. The cat kidney cell line, named CRFK-BLA, is deposited in China general microbiological culture Collection center, address: the collection number of the institute of microbiology of China, national academy of sciences, no. 3, of West Lu No. 1, north Star, of the Chaoyang district, beijing, is CGMCC NO:45703 classified as: cat kidney cells, date of preservation: 2023 8 month 17 day. The serum-free full suspension culture type CRFK cell line obtained by domestication on the basis is named CRFK-BLB and is preserved in China general microbiological culture Collection center, address: the collection number of the institute of microbiology of China, national academy of sciences, no. 3, of West Lu No. 1, north Star, of the Chaoyang district, beijing, is CGMCC NO:45704, classified and named: cat kidney suspension cells, date of preservation: 2023 8 month 17 day. The cell morphology is mainly uniform transparent circles; the virus sensitivity test shows that the cat kidney suspension cell line is sensitive to cat parvovirus, canine parvovirus, feline panleukopenia virus, feline calicivirus, feline infectious rhinotracheitis virus and mink viral enteritis virus; the cell line can be used for culturing, separating and detecting viruses, preparing virus vaccines and screening medicaments for preventing or treating diseases caused by virus infection.
PCT No. PCT/EP94/03866 Sec. 371 Date Aug. 5, 1996 Sec. 102(e) Date Aug. 5, 1996 PCT Filed Nov. 23, 1994 PCT Pub. No. WO95/15158 PCT Pub. Date Jun. 8, 1995An active substance-containing patch for the controlled release of active substances, comprising a backing layer, an adjoining active substance-containing reservoir layer softening at body temperature, a membrane controlling the active substance release, a pressure-sensitive adhesive device permitting fixation of the patch to the skin, and a removable protective layer, is characterized by the fact that the reservoir layer which softens at body temperature is spaced away from the controlling membrane by means of a device made of a material impermeable to the active substance which extends all over the mutually facing surfaces of the reservoir and the membrane and which has at least one passage for the reservoir layer which softens at body temperature.
All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin immediate release (IR) 500 mg q12h following a moderate fat meal for 5 days (Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q24h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).